

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US04/042691

International filing date: 17 December 2004 (17.12.2004)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/539,637
Filing date: 28 January 2004 (28.01.2004)

Date of receipt at the International Bureau: 24 January 2005 (24.01.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1274199

UNITED STATES PATENT AND TRADEMARK OFFICE

U. S. DEPARTMENT OF COMMERCE, WASHINGTON, D. C. 20540

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

January 14, 2005

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A
FILING DATE.


APPLICATION NUMBER: 60/539,637

FILING DATE: *January 28, 2004*

RELATED PCT APPLICATION NUMBER: PCT/US04/42691



Certified By



Jon W Dudas

Under Secretary
of Commerce for Intellectual Property
and Acting Director of the
United States Patent and Trademark Office

012804
16138 U.S. PTO

SUBSTITUTE for Provisional Application for Patent Cover Sheet PTO/SB/16 (08-03)
 Approved for use through 07/31/2006. OMB 0651-0032
 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a **PROVISIONAL APPLICATION FOR PATENT** under 37 CFR 1.53 (c).

DOCKET NUMBER	21603PV2
---------------	----------

INVENTOR(S)

Given Name (first and middle [if any])	Family Name or Surname	Residence (City and either State or Foreign Country)
Michael R. Neville J. Mark G.	Wood Anthony Bock	Harleysville, PA 19438 Hatfield, PA 19440 Hatfield, PA 19440

22151 U.S. PTO
60/539,637
012804

Additional inventors are being named on the separately numbered sheets attached hereto

TITLE OF THE INVENTION (500 characters max)

ALPHA-HYDROXY AMIDES AS BRADYKININ ANTAGONISTS OR INVERSE AGONISTS

CORRESPONDENCE ADDRESS

Direct all Correspondence to:

Merck & Co., Inc.
Patent Department - RY60-30
P.O. Box 2000
Rahway

Customer Number 000210

STATE	ZIP CODE	COUNTRY	U.S.A.
New Jersey	07065		

ENCLOSED APPLICATION PARTS (check all that apply)

<input checked="" type="checkbox"/> Specification	Number of Pages	40	<input type="checkbox"/> CD(s), Number	
<input type="checkbox"/> Drawing(s)	Number of Sheets		<input type="checkbox"/> Other (specify)	
<input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76				

METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT (check one)

<input type="checkbox"/> A check or money order is enclosed to cover the filing fees	<input checked="" type="checkbox"/> The Director is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: 13-2755	FILING FEE AMOUNT (\$)	\$160.00
--	--	------------------------	----------

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

No.

Yes, the name of the U.S. Government agency and the Government contract number are: _____

Respectfully submitted,

SIGNATURE 

TYPED or PRINTED NAME Mollie M. Yang

TELEPHONE (732) 594-6343

Date 01/28/2004

REGISTRATION NO. 32,718

NOTE: Mail to Mail Stop Provisional Application

EXPRESS MAIL CERTIFICATE	
DATE OF DEPOSIT January 28, 2004	
EXPRESS MAIL NO. EV 321984087 US	
<p>I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE" ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450:</p>	
MAILED BY 	DATE January 28, 2004

In Duplicate

TITLE OF THE INVENTION

α -HYDROXY AMIDES AS BRADYKININ ANTAGONISTS OR INVERSE AGONISTS

BACKGROUND OF THE INVENTION

5 This invention is directed to α -hydroxyamide compounds. In particular, this invention is directed to α -hydroxyamide compounds that are bradykinin antagonists or inverse agonists.

10 Bradykinin ("BK") is a kinin which plays an important role in the pathophysiological processes accompanying acute and chronic pain and inflammation.

15 Bradykinin (BK), like other kinins, is an autacoid peptide produced by the catalytic action of kallikrein enzymes on plasma and tissue precursors termed kininogens. The biological actions of BK are mediated by at least two major G-protein-coupled BK receptors termed B1 and B2. It is generally believed that B2 receptors, but not B1 receptors, are expressed in normal tissues and that inflammation, tissue damage or bacterial infection can rapidly induce B1 receptor expression. This makes the B1 receptor a particularly attractive drug target. The putative role of kinins, and specifically BK, in the management of pain and inflammation has provided the impetus for developing potent and selective BK antagonists. In recent years, this effort has been heightened with the expectation that useful therapeutic agents with analgesic and anti-inflammatory properties would provide relief from maladies mediated through a BK receptor pathway (see e.g., M.G. Bock and J. Longmore, *Current Opinion in Chem. Biol.*, 4:401-406(2000)). Accordingly, there is a need for novel compounds that are effective in blocking or reversing activation of bradykinin receptors. Such compounds would be useful in the management of pain and inflammation, as well as in the treatment or prevention of diseases and disorders mediated by bradykinin; further, such compounds are also useful as research tools (*in vivo* and *in vitro*).

20


25

SUMMARY OF THE INVENTION

30 The present invention provides α -hydroxy amide derivatives which are bradykinin antagonists or inverse agonists, pharmaceutical compositions containing such compounds, and methods of using them as therapeutic agents.

DETAILED DESCRIPTION OF THE INVENTION


The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof



wherein

Y is CH or N;

10 R¹ is



15 R^{2a} and R^{2b} are independently selected from (1) a group selected from Ra, (2) (CH₂)_nNR^bC(O)Ra, (3) (CH₂)_nNR^bSO₂Rd, (4) (CH₂)_nNR^bCO₂Ra, (5) (CH₂)_k-heterocycle optionally substituted with 1 to 3 groups independently selected from halogen, nitro, cyano, OR^a, SR^a, C₁₋₄ alkyl and C₁₋₃ haloalkyl wherein said heterocycle is (a) a 5-membered heteroaromatic ring having a ring heteroatom selected from N, O and S, and optionally having up to 3 additional ring nitrogen atoms wherein said ring is optionally benzo-fused; or (b) a 6-membered heteroaromatic ring containing from 1 to 3 ring nitrogen atoms and N-oxides thereof, wherein said ring is optionally benzo-fused, (6) (CH₂)_kCO₂R^a, and (7) (CH₂)_kC(O)NR^bRc, or

20 R^{2a} and R^{2b} together with the carbon atom to which they are attached form a 3- to 7-membered carbocyclic ring optionally substituted with 1 to 4 groups independently selected from halogen, OR^a, C₁₋₄ alkyl and C₁₋₄ haloalkyl;

25 R^{3a} and R^{3b} are independently selected from hydrogen and C₁₋₄ alkyl optionally substituted with 1 to 5 halogen atoms;

R^{4a} and R^{4b} are independently selected from hydrogen and halogen;

R⁶ is selected from (1) C₁₋₈ alkyl optionally substituted with 1-5 groups independently selected from halogen, nitro, cyano, COR^a, CO₂R^a, C(O)NR^bRc, OR^a, OC(O)Ra, SR^a, SO₂Rd, S(O)Rd,

NR^bRC, NR^bC(O)Ra, NR^bSO₂Rd, and NR^bCO₂Ra, (2) C₃₋₈ cycloalkyl, (3) C₂₋₈ alkenyl optionally substituted with CO₂Ra, (4) halogen, (5) cyano, (6) nitro, (7) NR^bRC, (8) NR^bC(O)Ra, (9) NR^bCO₂Ra, (10) NR^bC(O)NR^bRC, (11) NR^bC(O)NR^bCO₂Ra, (12) NR^bSO₂Rd, (13) CO₂Ra, (14) CORa, (15) C(O)NR^bRC, (16) C(O)NHORA, (17) C(=NORA)Ra, (18) C(=NORA)NR^bRC, (19) ORa, (20) OC(O)Ra, (21) S(O)_nRd, (22) SO₂NR^bRC, (23) 5 optionally substituted heterocycle where the heterocycle is a 5-membered heteroaromatic ring having a ring heteroatom selected from N, O and S, and optionally having up to 3 additional ring nitrogen atoms, 4,5-dihydro-oxazolyl or 4,5-dihydro-1,2,4-oxadiazolyl, and wherein said substituent is 1 to 3 groups independently selected from C₁₋₄ alkyl optionally substituted with 1 to 5 halogen atoms, ORa or OC(O)Ra, (24) phenyl or pyridyl, each optionally substituted with 1 to 3 groups independently selected from halogen, nitro, cyano, ORa, SRa, C₁₋₄ alkyl and C₁₋₃ haloalkyl, and (25) OSO₂Rd;

10 R⁷ is selected from hydrogen and halogen;

15 R⁸ and R⁹ are independently selected from hydrogen and a group from R⁶; with the proviso that not more than one of R⁶, R⁸, and R⁹ is a heterocycle;

20 R^a is selected from (1) hydrogen, (2) C₁₋₇ alkyl optionally substituted with 1 to 5 halogen atoms, SH, OH, S-C₁₋₄alkyl or OC₁₋₄alkyl, (3) (CH₂)_k-phenyl optionally substituted with 1 to 3 groups independently selected from halogen, cyano, nitro, OH, C₁₋₄ alkyloxy, C₃₋₆ cycloalkyl and C₁₋₄ alkyl optionally substituted with 1 to 5 halogen atoms, (4) C₃₋₆ cycloalkyl, (5) (CH₂)_k-pyridyl, and (6) (CH₂)_k-indolyl;

25 R^b and R^c are independently selected from (1) hydrogen, (2) C₁₋₄ alkyl optionally substituted with 1 to 5 groups independently selected from halogen, amino, CO₂Ra, ORa, mono-C₁₋₄alkylamino, and di-C₁₋₄alkylamino, (3) (CH₂)_k-phenyl optionally substituted with 1 to 3 groups selected from halogen, cyano, nitro, ORa, CO₂Ra, C₃₋₆ cycloalkyl and C₁₋₄ alkyl optionally substituted with 1 to 5 halogen atoms, and (4) C₃₋₆ cycloalkyl, or

30 R^b and R^c together with the nitrogen atom to which they are attached form a 4-, 5-, or 6-membered ring optionally containing an additional heteroatom selected from NRe, O, S, S(O) and S(O)₂;

R^d is selected from (1) C₁₋₄ alkyl optionally substituted with 1 to 5 halogen atoms, (2) C₁₋₄ alkyloxy, (3) (CH₂)_k-phenyl optionally substituted with 1 to 3 groups selected from halogen, cyano, nitro, ORa, CO₂Ra, C₃₋₆ cycloalkyl and C₁₋₄ alkyl optionally substituted with 1 to 5 halogen atoms, (4) pyridyl, and (5) pyridyl N-oxide;

R^e is selected from hydrogen, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C(O)H and C(O)C₁₋₄alkyl;

n is 1, 2, or 3;

k is 0, 1, 2, 3, or 4; and

v is 0, 1, or 2.

Examples of R_{2a} and R_{2b} include, without limitation, hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, t-butyl, n-pentyl, neo-pentyl, n-hexyl, n-heptyl, trifluoromethyl, 2,2,2-trifluoroethyl, 1,1-difluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, phenyl, benzyl, *o*-, *m*- or *p*-tolyl, xylyl, (trifluoromethyl)phenyl, cyanophenyl, bromophenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, hydroxyphenyl, dihydroxyphenyl, methoxyphenyl, dimethoxyphenyl, (hydroxy)(methoxy)phenyl, 3-indolylmethyl, pyrrolyl, thiazolyl, oxazolyl, imidazolyl, 2-benzothienyl, isoxazolyl, isothiazolyl, quinolinyl, 2-(acethylamino)ethyl, (methylsulfonylamino)methyl, carboxy, carbamoylmethyl, and 2-(methoxycarbonylamino)ethyl. R_{2a}, R_{2b} and the carbon to which they are attached together may form cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl, each of which may be optionally substituted with 1 or 4 groups, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, t-butyl, chlorine, fluorine, bromine, chloromethyl, trifluoromethyl, 1-chloroethyl, hydroxy, methoxy, and ethoxy.


Examples of R_{3a} and R_{3b} include, without limitation, hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, t-butyl, chloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, 2,2-difluoroethyl, 1,1,2,2,2-pentafluoroethyl, and the like.

Examples of R₆ include methyl, ethyl, 1-methylethyl, 1-hydroxyethyl, carboxy, methoxycarbonyl, ethoxycarbonyl, 2-fluoroethoxycarbonyl, isopropoxycarbonyl, phenoxy-carbonyl, cyclopentoxycarbonyl, cyclobutoxycarbonyl, cyclopropoxycarbonyl, 2,2,2-trifluoroethoxycarbonyl, 4-trifluoromethylphenoxy carbonyl, methoxyaminocarbonyl, methoxycarbonylmethyl, formyl, hydroxy, 5-methyl-1,2,4-oxadiazol-3-yl, 3-methyl-1,2,4-oxadiazol-5-yl, 1-methyl-5-tetrazolyl, 2-methyl-5-tetrazolyl, cyano, methoxy, ethoxy, difluoromethoxy, trifluoromethoxy, 2,2-difluoroethoxy, 1,3-difluoropropoxy, 2,2,2-trifluoroethoxy, trifluoromethyl, chloro, fluoro, methylaminosulfonyl, dimethylaminosulfonyl, methoxycarbonylamino, ethoxycarbonyl-amino, 2-fluoroethoxycarbonyl-amino, methylaminocarbonyl-amino, dimethylamino, methyl-aminocarbonyl, isopropylaminocarbonyl, ethylaminocarbonyl, cyclopropylaminocarbonyl, cyclobutylaminocarbonyl, dimethylaminocarbonyl, and aminocarbonyl. Examples for R₈ include hydrogen, chloro, fluoro and methoxycarbonyl; examples of R₉ include hydrogen, chloro, fluoro and methyl.

In one subset of formula I are compounds wherein R_{2a}, R_{2b} and the carbon atom to which they are attached form a 3- to 7-membered carbocyclic ring, said ring being optionally substituted with 1 to 4 groups independently selected from methyl and halogen.


In a second subset of formula I are compounds wherein one of R^{3a} and R^{3b} is hydrogen and the other is hydrogen or methyl.

In a third subset of formula I are compounds wherein R¹ is




5 In one embodiment within this subset are compounds wherein R⁶ is selected from (1) -CO₂-C₁₋₄alkyl, (2) C₁₋₄alkoxy, and (3) a 5-membered heteroaromatic ring having a ring heteroatom selected from N, O and S, and optionally having up to 3 additional ring nitrogen atoms, said ring being optionally substituted with a C₁₋₄alkyl group. In one embodiment R⁶ is selected from methoxycarbonyl, ethoxy, 1,2,4-oxadiazolyl optionally substituted with a methyl group, and terazolyl optionally substituted with a methyl group. In another embodiment within 10 this subset are compounds wherein R⁸ is hydrogen or 3-halogen. In yet another embodiment within this subset are compounds wherein R⁸ is hydrogen or 3-halogen, and R⁹ is hydrogen or 5-halogen.

In a fourth subset of formula I are compounds of formula (Ia):




15 wherein m is 1 to 5; Y is N or CH; one of R^{3a} and R^{3b} is hydrogen and the other is hydrogen or methyl; R⁷ is hydrogen or fluorine; R⁶ is selected from (1) -CO₂-C₁₋₄alkyl, (2) C₁₋₄alkoxy optionally substituted with 1 to 5 halogen atoms, and (3) a 5-membered heteroaromatic ring having a ring heteroatom selected from N, O and S, and optionally having up to 3 additional ring nitrogen atoms, said ring being optionally substituted with a C₁₋₄alkyl group; and R⁸ and R⁹ are independently hydrogen or halogen.

In a fifth subset of compounds of formula I are compounds wherein R¹ is



In one embodiment within this subset R^a is H. In another embodiment, R^{4a} and R^{4b} are each a halogen exemplified by fluorine.

In a sixth subset of compounds of formula I are compounds of formula Ib:



5


where R^{3a}, R^{3b}, R⁶, R⁷, R⁸ and R⁹ are as defined under formula I. R^{2a'} and R^{2b'} are independently selected from (1) hydrogen, (2) C₁₋₇ alkyl optionally substituted with 1 to 5 halogen atoms, SH, OH, S-C₁₋₄alkyl or OC₁₋₄alkyl, (3) (CH₂)_k-phenyl optionally substituted with 1 to 3 groups independently selected from halogen, cyano, nitro, OH, C₁₋₄ alkyloxy, C₃₋₆ cycloalkyl and C₁₋₄ alkyl optionally substituted with 1 to 5 halogen atoms, (4) C₃₋₆ cycloalkyl, (5) (CH₂)_k-pyridyl, and (6) (CH₂)_k-indolyl. In one embodiment within this subset are compounds wherein R^{2a'} and R^{2b'} are independently C₁₋₇alkyl optionally substituted with 1 to 5 halogen atoms. In another embodiment are compounds wherein one of R^{3a} and R^{3b} is hydrogen and the other is hydrogen or methyl; R⁷ is hydrogen or fluorine; R⁶ is selected from (1) -CO₂-C₁₋₄alkyl, (2) C₁₋₄alkoxy optionally substituted with 1 to 5 halogen atoms, and (3) a 5-membered heteroaromatic ring having a ring heteroatom selected from N, O and S, and optionally having up to 3 additional ring nitrogen atoms, said ring being optionally substituted with a C₁₋₄alkyl group; and R⁸ and R⁹ are independently hydrogen or halogen.

10

15

20

In a seventh subset of compounds of formula I are compounds of formula Ic:



5 wherein Y is N or CH; R⁷ is H or fluroine; R⁶ is selected from (1) -CO₂-C₁₋₄alkyl, (2) C₁₋₄alkoxy optionally substituted with 1 to 5 halogen atoms, and (3) a 5-membered heteroaromatic ring having a ring heteroatom selected from N, O and S, and optionally having up to 3 additional ring nitrogen atoms, said ring being optionally substituted with a C₁₋₄alkyl group; and R⁸ and R⁹ are independently hydrogen or halogen. In one embodiment, R⁸ is fluorine or chlorine. In another embodiment R⁸ and R⁹ are each chlorine.

10 A second aspect of the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

15 A third aspect of the present invention provides the use of a compound of formula I or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of conditions mediated by bradykinin B1 receptor. In one subset said condition is pain including inflammatory and neuropathic pain.

20 A fourth aspect of the present invention provides a method for the treatment of a condition mediated by bradykinin B1 receptor in a mammal comprising administering to said mammal a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

Unless otherwise stated, the following terms have the meanings indicated below:

25 "Alkenyl" means carbon chains which may be linear or branched or combination thereof and containing at least one C=C bond. Examples of alkenyl include allyl, 2-but enyl, 3-but enyl, 1-methyl-2-propenyl, and the like.

30 "Alkyl" as well as other groups having the prefix "alk" such as, for example, alkoxy, alkanoyl, and the like, means carbon chains which may be linear or branched or combinations thereof. Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec- and tert-butyl, pentyl, hexyl, heptyl and the like.

“Cycloalkyl” means carbocycles containing no heteroatoms, and includes mono-, bi- and tricyclic saturated carbocycles, as well as fused ring systems. Such fused ring systems can include one ring that is partially or fully unsaturated such as a benzene ring to form fused ring systems such as benzofused carbocycles. Cycloalkyl includes such fused ring systems as spiro-fused ring systems. Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, decahydronaphthalene, adamantane, indanyl, indenyl, fluorenyl, 1,2,3,4-tetrahydronaphthalene and the like.

“Haloalkyl” means an alkyl radical as defined above wherein at least one and up to all of the hydrogen atoms are replaced with a halogen. Examples of such haloalkyl radicals include chloromethyl, 1-bromoethyl, fluoromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl and the like.

“Halogen” means fluorine, chlorine, bromine and iodine.

“5-Membered heteroaromatic ring” and “benzo-fused 5-membered heteroaromatic ring” include, without limitation, pyrrole, imidazole, pyrazole, 1,2,3-triazole, 1,2,4-triazole, tetrazole, furan, thiophene, thiazole, oxazole, isothiazole, isoxazole, 1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,2,4-thiadiazole, 1,2,5-thiadiazole, benzofuran, benzothiophene, indole, benzimidazole, benzothiazole, benzoxazole, benzothiazole, and benzisoxazole.

“6-Membered heteroaromatic ring” and “benzo-fused 6-membered heteroaromatic ring” include, without limitation, pyridine, pyrimidine, pyridazine, pyrazine, triazine, quinoline, isoquinoline and quinoxaline.

Optical Isomers - Diastereomers - Geometric Isomers – Tautomers.

Compounds described herein may contain an asymmetric center and may thus exist as enantiomers. Where the compounds according to the invention possess two or more asymmetric centers, they may additionally exist as diastereomers. The present invention includes 5 all such possible stereoisomers as substantially pure resolved enantiomers, racemic mixtures thereof, as well as mixtures of diastereomers. The above Formula I is shown without a definitive stereochemistry at certain positions. The present invention includes all stereoisomers of Formula I and pharmaceutically acceptable salts thereof. Diastereomeric pairs of enantiomers may be separated by, for example, fractional crystallization from a suitable solvent, and the pair of 10 enantiomers thus obtained may be separated into individual stereoisomers by conventional means, for example by the use of an optically active acid or base as a resolving agent or on a chiral HPLC column. Further, any enantiomer or diastereomer of a compound of the general Formula I may be obtained by stereospecific synthesis using optically pure starting materials or reagents of known configuration.

15 Some of the compounds described herein contain olefinic double bonds, and unless specified otherwise, are meant to include both E and Z geometric isomers.

Some of the compounds described herein may exist with different points of attachment of hydrogen, referred to as tautomers. Such an example may be a ketone and its enol 20 form known as keto-enol tautomers. The individual tautomers as well as mixture thereof are encompassed with compounds of Formula I.

Salts.

The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids. When the compound of the present 25 invention is acidic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic bases, including inorganic bases and organic bases. Salts derived from such inorganic bases include aluminum, ammonium, calcium, copper (ic and ous), ferric, ferrous, lithium, magnesium, manganese (ic and ous), potassium, sodium, zinc and the like salts. Preferred are the ammonium, calcium, magnesium, potassium and sodium salts. Salts prepared 30 from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines derived from both naturally occurring and synthetic sources. Pharmaceutically acceptable organic non-toxic bases from which salts can be formed include, for example, arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-

ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, dicyclohexylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine and the like.

5 When the compound of the present invention is basic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic inorganic and organic acids. Such acids include, for example, acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, 10 succinic, sulfuric, tartaric, p-toluenesulfonic acid and the like. Preferred are citric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric, and tartaric acids.

Prodrugs.

15 The present invention includes within its scope prodrugs of the compounds of this invention. In general, such prodrugs will be functional derivatives of the compounds of this invention which are readily convertible in vivo into the required compound. Thus, in the methods of treatment of the present invention, the term "administering" shall encompass the treatment of the various conditions described with the compound specifically disclosed or with a compound which may not be specifically disclosed, but which converts to the specified compound in vivo 20 after administration to the patient. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs," ed. H. Bundgaard, Elsevier, 1985. Metabolites of these compounds include active species produced upon introduction of compounds of this invention into the biological milieu.

Pharmaceutical Compositions.

25 Another aspect of the present invention provides pharmaceutical compositions which comprises a compound of Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The term "composition", as in pharmaceutical composition, is intended to encompass a product comprising the active ingredient(s), and the inert 30 ingredient(s) (pharmaceutically acceptable excipients) that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients. Accordingly, the pharmaceutical compositions of the present invention encompass any composition made by

admixing a compound of Formula I, additional active ingredient(s), and pharmaceutically acceptable excipients.

The pharmaceutical compositions of the present invention comprise a compound represented by Formula I (or pharmaceutically acceptable salts thereof) as an active ingredient, a pharmaceutically acceptable carrier and optionally other therapeutic ingredients or adjuvants.

5 The compositions include compositions suitable for oral, rectal, topical, and parenteral (including subcutaneous, intramuscular, and intravenous) administration, although the most suitable route in any given case will depend on the particular host, and nature and severity of the conditions for which the active ingredient is being administered. The pharmaceutical

10 compositions may be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.

In practice, the compounds represented by Formula I, or pharmaceutically acceptable salts thereof, of this invention can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding

15 techniques. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral (including intravenous). Thus, the pharmaceutical compositions of the present invention can be presented as discrete units suitable for oral administration such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient. Further, the compositions can be presented as a powder, as

20 granules, as a solution, as a suspension in an aqueous liquid, as a non-aqueous liquid, as an oil-in-water emulsion or as a water-in-oil liquid emulsion. In addition to the common dosage forms set out above, the compound represented by Formula I, or pharmaceutically acceptable salts thereof, may also be administered by controlled release means and/or delivery devices. The compositions may be prepared by any of the methods of pharmacy. In general, such methods

25 include a step of bringing into association the active ingredient with the carrier that constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both. The product can then be conveniently shaped into the desired presentation.

Thus, the pharmaceutical compositions of this invention may include a pharmaceutically acceptable carrier and a compound or a pharmaceutically acceptable salt of Formula I. The compounds of Formula I, or pharmaceutically acceptable salts thereof, can also be included in pharmaceutical compositions in combination with one or more other therapeutically active compounds.

The pharmaceutical carrier employed can be, for example, a solid, liquid, or gas. Examples of solid carriers include lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid. Examples of liquid carriers are sugar syrup, peanut oil, olive oil, and water. Examples of gaseous carriers include carbon dioxide and nitrogen.

5 In preparing the compositions for oral dosage form, any convenient pharmaceutical media may be employed. For example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like may be used to form oral liquid preparations such as suspensions, elixirs and solutions; while carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like may
10 be used to form oral solid preparations such as powders, capsules and tablets. Because of their ease of administration, tablets and capsules are the preferred oral dosage units whereby solid pharmaceutical carriers are employed. Optionally, tablets may be coated by standard aqueous or nonaqueous techniques

15 A tablet containing the composition of this invention may be prepared by compression or molding, optionally with one or more accessory ingredients or adjuvants. Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent.
20 Each tablet preferably contains from about 0.1mg to about 500mg of the active ingredient and each cachet or capsule preferably containing from about 0.1mg to about 500mg of the active ingredient.

25 Pharmaceutical compositions of the present invention suitable for parenteral administration may be prepared as solutions or suspensions of the active compounds in water. A suitable surfactant can be included such as, for example, hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Further, a preservative can be included to prevent the detrimental growth of microorganisms.

30 Pharmaceutical compositions of the present invention suitable for injectable use include sterile aqueous solutions or dispersions. Furthermore, the compositions can be in the form of sterile powders for the extemporaneous preparation of such sterile injectable solutions or dispersions. In all cases, the final injectable form must be sterile and must be effectively fluid for easy syringability. The pharmaceutical compositions must be stable under the conditions of manufacture and storage; thus, preferably should be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium

containing, for example, water, ethanol, polyol (e.g. glycerol, propylene glycol and liquid polyethylene glycol), vegetable oils, and suitable mixtures thereof.

Pharmaceutical compositions of the present invention can be in a form suitable for topical use such as, for example, an aerosol, cream, ointment, lotion, dusting powder, or the like.

5 Further, the compositions can be in a form suitable for use in transdermal devices. These formulations may be prepared, utilizing a compound represented by Formula I of this invention, or pharmaceutically acceptable salts thereof, via conventional processing methods. As an example, a cream or ointment is prepared by mixing hydrophilic material and water, together with about 5 wt% to about 10 wt% of the compound, to produce a cream or ointment having a

10 desired consistency.

15 Pharmaceutical compositions of this invention can be in a form suitable for rectal administration wherein the carrier is a solid. It is preferable that the mixture forms unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art. The suppositories may be conveniently formed by first admixing the composition with the softened or melted carrier(s) followed by chilling and shaping in moulds.

20 In addition to the aforementioned carrier ingredients, the pharmaceutical formulations described above may include, as appropriate, one or more additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including anti-oxidants) and the like. Furthermore, other adjuvants can be included to render the formulation isotonic with the blood of the intended recipient. Compositions containing a compound described by Formula I, or pharmaceutically acceptable salts thereof, may also be prepared in powder or liquid concentrate form.

The following are examples of representative pharmaceutical dosage forms for the compounds of Formula I:

25

Inj. Suspension (I.M.)	mg/mL	Tablet	mg/tab.	Capsule	mg/cap.
Cmpd of Formula I	10	Cmpd of Formula I	25	Cmpd of Formula I	25
Methylcellulose	5.0	Microcryst. Cellulose	415	Lactose Powder	573.5
Tween 80	0.5	Povidone	14.0	Magnesium Stearate	1.5
Benzyl alcohol	9.0	Pregelatinized Starch	43.5		600
Benzalkonium chloride	1.0	Magnesium Stearate	2.5		
Water for injection to a total volume of 1 mL			500		

Utilities

Compounds of this invention are antagonists or inverse agonists of bradykinin receptor, in particular the bradykinin B1 receptor, and as such are useful in the treatment and prevention of diseases and conditions mediated through the bradykinin receptor pathway such as pain and inflammation. The compounds would be effective in the treatment or prevention of pain including, for example, visceral pain (such as pancreatitis, interstitial cystitis, renal colic, prostatitis, chronic pelvic pain), neuropathic pain (such as postherpetic neuralgia, acute zoster pain, nerve injury, the “dynias”, e.g., vulvodynia, phantom limb pain, root avulsions, radiculopathy, painful traumatic mononeuropathy, painful entrapment neuropathy, carpal tunnel syndrome, ulnar neuropathy, tarsal tunnel syndrome, painful diabetic neuropathy, painful polyneuropathy, trigeminal neuralgia), central pain syndromes (potentially caused by virtually any lesion at any level of the nervous system including but not limited to stroke, multiple sclerosis, spinal cord injury), and postsurgical pain syndromes (e.g., postmastectomy syndrome, postthoracotomy syndrome, stump pain)), bone and joint pain (osteoarthritis), spine pain (e.g., acute and chronic low back pain, neck pain, spinal stenosis), shoulder pain, repetitive motion pain, dental pain, sore throat, cancer pain, myofascial pain (muscular injury, fibromyalgia), postoperative, perioperative pain and preemptive analgesia (including but not limited to general surgery, orthopedic, and gynecological), chronic pain, dysmenorrhea (primary and secondary), as well as pain associated with angina, and inflammatory pain of varied origins (e.g. osteoarthritis, rheumatoid arthritis, rheumatic disease, teno-synovitis and gout, ankylosing spondylitis, bursitis).

Further, the compounds of this invention can also be used to treat hyperreactive airways and to treat inflammatory events associated with airways disease e.g. asthma including allergic asthma (atopic or non-atopic) as well as exercise-induced bronchoconstriction, occupational asthma, viral- or bacterial exacerbation of asthma, other non-allergic asthmas and “wheezy-infant syndrome”. Compounds of the present invention may also be used to treat chronic obstructive pulmonary disease including emphysema, adult respiratory distress syndrome, bronchitis, pneumonia, allergic rhinitis (seasonal and perennial), and vasomotor rhinitis. They may also be effective against pneumoconiosis, including aluminosis, anthracosis, asbestosis, chalcosis, ptilosis, siderosis, silicosis, tabacosis and byssinosis.

Compounds of the present invention may also be used for the treatment of inflammatory bowel disease including Crohn’s disease and ulcerative colitis, irritable bowel syndrome, pancreatitis, nephritis, cystitis (interstitial cystitis), uveitis, inflammatory skin disorders such as psoriasis and eczema, rheumatoid arthritis and edema resulting from trauma associated with burns, sprains or fracture, cerebral edema and angioedema. They may be used to treat diabetic vasculopathy, diabetic neuropathy, diabetic retinopathy, post capillary resistance or

diabetic symptoms associated with insulitis (e.g. hyperglycemia, diuresis, proteinuria and increased nitrite and kallikrein urinary excretion). They may be used as smooth muscle relaxants for the treatment of spasm of the gastrointestinal tract or uterus. Additionally, they may be effective against liver disease, multiple sclerosis, cardiovascular disease, e.g. atherosclerosis, 5 congestive heart failure, myocardial infarct; neurodegenerative diseases, eg. Parkinson's and Alzheimers disease, epilepsy, septic shock e.g. as anti-hypovolemic and/or anti-hypotensive agents, headache including cluster headache, migraine including prophylactic and acute use, stroke, closed head trauma, cancer, sepsis, gingivitis, osteoporosis, benign prostatic hyperplasia and hyperactive bladder. Animal models of these diseases and conditions are generally well 10 known in the art, and may be suitable for evaluating compounds of the present invention for their potential utilities. Finally, compounds of the present invention are also useful as research tools (*in vivo* and *in vitro*).

The compounds of this invention are useful in the treatment of pain and inflammation by the administration of a tablet, cachet, or capsule each containing, for example, 15 0.1mg, 0.5mg, 1mg, 3mg, 5mg, 10mg, 25mg, 50mg, 100mg, 125mg, 250mg, or 500mg of a compound of this invention once every three to four hours, once, twice or three times a day, or (in an extended release formulation) once, twice or three times a week.

The compounds would be effective in the treatment or prevention of pain including, for example, bone and joint pain (osteoarthritis), repetitive motion pain, dental pain, 20 cancer pain, myofascial pain (muscular injury, fibromyalgia), perioperative pain (general surgery, oral surgery, gynecological), neuropathic pain (post-herpetic neuralgia), and chronic pain by the administration of a tablet, cachet, or capsule each containing, for example, 0.1mg, 0.5mg, 1mg, 3mg, 5mg, 10mg, 25mg, 50mg, 100mg, 125mg, 250mg, or 500mg of a compound of this invention once every three to four hours, once, twice or three times a day, or (in an extended 25 release formulation) once, twice or three times a week.

In particular, inflammatory pain such as, for example, inflammatory airways disease (chronic obstructive pulmonary disease) would be effectively treated by the compounds of this invention by the administration of a tablet, cachet, or capsule each containing, for example, 0.1mg, 0.5mg, 1mg, 3mg, 5mg, 10mg, 25mg, 50mg, 100mg, 125mg, 250mg, or 500mg 30 of a compound of this invention once every three to four hours, once, twice or three times a day, or (in an extended release formulation) once, twice or three times a week.

Further, the compounds of this invention can additionally be used to treat asthma, inflammatory bowel disease, rhinitis, pancreatitis, cystitis (interstitial cystitis), uveitis, inflammatory skin disorders, rheumatoid arthritis and edema resulting from trauma associated 35 with burns, sprains or fracture by the administration of a tablet, cachet, or capsule each

containing, for example, 0.1mg, 0.5mg, 1mg, 3mg, 5mg, 10mg, 25mg, 50mg, 100mg, 125mg, 250mg, or 500mg of a compound of this invention once every three to four hours, once, twice or three times a day, or (in an extended release formulation) once, twice or three times a week.

They may be used subsequent to surgical intervention (e.g. as post-operative analgesics) and to treat inflammatory pain of varied origins (e.g. osteoarthritis, rheumatoid arthritis, rheumatic disease, teno-synovitis and gout) as well as for the treatment of pain associated with angina, menstruation or cancer by the administration of a tablet, cachet, or capsule each containing, for example, 0.1mg, 0.5mg, 1mg, 3mg, 5mg, 10mg, 25mg, 50mg, 100mg, 125mg, 250mg, or 500mg of a compound of this invention once every three to four hours, once, twice or three times a day, or (in an extended release formulation) once, twice or three times a week.

They may be used to treat diabetic vasculopathy, post capillary resistance or diabetic symptoms associated with insulitis (e.g. hyperglycemia, diuresis, proteinuria and increased nitrite and kallikrein urinary excretion) by the administration of a tablet, cachet, or capsule each containing, for example, 0.1mg, 0.5mg, 1mg, 3mg, 5mg, 10mg, 25mg, 50mg, 100mg, 125mg, 250mg, or 500mg of a compound of this invention once every three to four hours, once, twice or three times a day, or (in an extended release formulation) once, twice or three times a week.

They may be used to treat inflammatory skin disorders such as psoriasis and eczema by the administration of a tablet, cachet, or capsule each containing, for example, 0.1mg, 0.5mg, 1mg, 3mg, 5mg, 10mg, 25mg, 50mg, 100mg, 125mg, 250mg, or 500mg of a compound of this invention once every three to four hours, once, twice or three times a day, or (in an extended release formulation) once, twice or three times a week.

They may be used as smooth muscle relaxants for the treatment of spasm of the gastrointestinal tract or uterus or in the therapy of Crohn's disease, ulcerative colitis or pancreatitis by the administration of a tablet, cachet, or capsule each containing, for example, 0.1mg, 0.5mg, 1mg, 3mg, 5mg, 10mg, 25mg, 50mg, 100mg, 125mg, 250mg, or 500mg of a compound of this invention once every three to four hours, once, twice or three times a day, or (in an extended release formulation) once, twice or three times a week.

Such compounds may be used therapeutically to treat hyperreactive airways and to treat inflammatory events associated with airways disease e.g. asthma, and to control, restrict or reverse airways hyperreactivity in asthma by the administration of a tablet, cachet, or capsule each containing, for example, 0.1mg, 0.5mg, 1mg, 3mg, 5mg, 10mg, 25mg, 50mg, 100mg, 125mg, 250mg, or 500mg of a compound of this invention once every three to four hours, once,

twice or three times a day, or (in an extended release formulation) once, twice or three times a week.

They may be used to treat intrinsic and extrinsic asthma including allergic asthma (atopic or non-atopic) as well as exercise-induced bronchoconstriction, occupational asthma, 5 viral or bacterial exacerbated asthma, other non-allergic asthmas and “wheezy-infant syndrome” by the administration of a tablet, cachet, or capsule each containing, for example, 0.1mg, 0.5mg, 1mg, 3mg, 5mg, 10mg, 25mg, 50mg, 100mg, 125mg, 250mg, or 500mg of a compound of this invention once every three to four hours, once, twice or three times a day, or (in an extended release formulation) once, twice or three times a week.

10 They may also be effective against pneumoconiosis, including aluminosis, anthracosis, asbestosis, chalcosis, ptilosis, siderosis, silicosis, tabacosis and byssinosis as well as adult respiratory distress syndrome, chronic obstructive pulmonary or airways disease, bronchitis, allergic rhinitis, and vasomotor rhinitis by the administration of a tablet, cachet, or capsule each containing, for example, 0.1mg, 0.5mg, 1mg, 3mg, 5mg, 10mg, 25mg, 50mg, 15 100mg, 125mg, 250mg, or 500mg of a compound of this invention once every three to four hours, once, twice or three times a day, or (in an extended release formulation) once, twice or three times a week.

20 Additionally, they may be effective against liver disease, multiple sclerosis, atherosclerosis, Alzheimer's disease, septic shock e.g. as anti-hypovolemic and/or anti-hypotensive agents, cerebral edema, headache including cluster headache, migraine including prophylactic and acute use, closed head trauma, irritable bowel syndrome and nephritis by the administration of a tablet, cachet, or capsule each containing, for example, 0.1mg, 0.5mg, 1mg, 3mg, 5mg, 10mg, 25mg, 50mg, 100mg, 125mg, 250mg, or 500mg of a compound of this invention once every three to four hours, once, twice or three times a day, or (in an extended 25 release formulation) once, twice or three times a week.

Combination Therapy

Compounds of Formula I may be used in combination with other drugs that are used in the treatment/prevention/suppression or amelioration of the diseases or conditions for 30 which compounds of Formula I are useful. Such other drugs may be administered, by a route and in an amount commonly used therefor, contemporaneously or sequentially with a compound of Formula I. When a compound of Formula I is used contemporaneously with one or more other drugs, a pharmaceutical composition containing such other drugs in addition to the compound of Formula I is preferred. Accordingly, the pharmaceutical compositions of the present invention 35 include those that also contain one or more other active ingredients, in addition to a compound of

Formula I. Examples of other active ingredients that may be combined with a compound of Formula I, either administered separately or in the same pharmaceutical compositions, include, but are not limited to: (1) morphine and other opiate receptor agonists including propoxyphene (Darvon) and tramadol; (2) non-steroidal antiinflammatory drugs (NSAIDs) including COX-2 inhibitors such as propionic acid derivatives (alminoprofen, benoxaprofen, bucloxic acid, carprofen, fenbufen, fenoprofen, fluprofen, flurbiprofen, ibuprofen, indoprofen, ketoprofen, mioprofen, naproxen, oxaprozin, pirprofen, pranoprofen, suprofen, tiaprofenic acid, and tioxaprofen), acetic acid derivatives (indomethacin, acemetacin, alclofenac, clidanac, diclofenac, fenclofenac, fenclozic acid, fentiazac, furofenac, ibufenac, isoxepac, oxpipac, sulindac, tiopinac, tolmetin, zidometacin, and zomepirac), fenamic acid derivatives (flufenamic acid, meclofenamic acid, mefenamic acid, niflumic acid and tolfenamic acid), biphenylcarboxylic acid derivatives (diflunisal and flufenisal), oxicams (isoxicam, piroxicam, sudoxicam and tenoxicam), salicylates (acetyl salicylic acid, sulfasalazine) and the pyrazolones (apazone, bezpiperylon, feprazone, mofebutazone, oxyphenbutazone, phenylbutazone), and the coxibs (celecoxib, valecoxib, rofecoxib and etoricoxib); (3) corticosteroids such as betamethasone, budesonide, cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone and triamcinolone; (4) histamine H1 receptor antagonists such as brompheniramine, chlorpheniramine, dexchlorpheniramine, triprolidine, clemastine, diphenhydramine, diphenylpyraline, tripeleannamine, hydroxyzine, methdilazine, promethazine, trimeprazine, azatadine, cyproheptadine, antazoline, pheniramine pyrilamine, astemizole, terfenadine, loratadine, cetirizine, desloratadine, fexofenadine and levocetirizine; (5) histamine H2 receptor antagonists such as cimetidine, famotidine and ranitidine; (6) proton pump inhibitors such as omeprazole, pantoprazole and esomeprazole; (7) leukotriene antagonists and 5-lipoxygenase inhibitors such as zafirlukast, montelukast, pranlukast and zileuton; (8) drugs used for angina, myocardial ischemia including nitrates such as nitroglycerin and isosorbide nitrates, beta blockers such as atenolol, metoprolol, propranolol, acebutolol, betaxolol, bisoprolol, carteolol, labetalol, nadolol, oxprenolol, penbutolol, pindolol, sotalol and timolol, and calcium channel blockers such as diltiazem, verapamil, nifedipine, bepridil, felodipine, flunarizine, isradipine, nicardipine and nimodipine; (9) incontinence medications such as antimuscarinics, e.g., tolterodine and oxybutinin; (10) gastrointestinal antispasmodics (such as atropine, scopolamine, dicyclomine, antimuscarinics, as well as diphenoxylate); skeletal muscle relaxants (cyclobenzaprine, carisoprodol, chlorphenesin, chlorzoxazone, metaxalone, methocarbamol, baclofen, dantrolene, diazepam, or orphenadrine); (11) gout medications such as allopurinol, probenecid and colchicine; (12) drugs for rheumatoid arthritis such as methotrexate, auranofin, aurothioglucose and gold sodium thiomalate; (13) drugs for osteoporosis such as alendronate and raloxifene;

decongestants such as pseudoephedrine and phenylpropanolamine; (14) local anesthetics; (15) anti-herpes drugs such as acyclovir, valacyclovir and famcyclovir; (16) anti-emetics such as ondansetron and granisetron; (17) migraine drugs such as the triptans (e.g. rizatriptan, sumatriptan), ergotamine, dihydroergotamine, CGRP antagonists, antidepressants (e.g., tricyclic anti-depressants, serotonin-selective reuptake inhibitors, beta-adrenergic blockers); (18) VR1 antagonists; (19) anticonvulsants (e.g., gabapentin, pregabalin, lamotrigine, topiramate, carbamazepine, oxcarbazepine, phenytoin); (20) glutamate antagonists (e.g., ketamine and other NMDA antagonists, NR2B antagonists); (21) acetaminophen; (22) CCR2 antagonists; (23) PDE4 antagonists.

10

Biological Evaluation

15 (a) Assessing the Affinity of Selected Compounds to Bind to the Bradykinin B1 or B2 Receptor

20 Radioligand binding assays are performed using membranes from CHO cells that stably express the human, rabbit, rat, or dog B1 receptors or CHO cells that express the human B2 receptor. For all receptor types, cells are harvested from culture flasks in PBS/1mM EDTA and centrifuged at 1000xg for 10 minutes. The cell pellets are homogenized with a polytron in ice cold 20mM HEPES, 1mM EDTA, pH 7.4 (lysis buffer) and centrifuged at 20,000xg for 20 minutes. The membrane pellets are rehomogenized in lysis buffer, centrifuged again at 20,000xg and the final pellets are resuspended at 5mg protein/ml in assay buffer (120mM NaCl, 5mM KCl, 20mM HEPES, pH 7.4) supplemented with 1% BSA and frozen at -80°C.

25 On the day of assay, membranes are centrifuged at 14,000xg for 5 minutes and resuspended to the desired protein concentration in assay buffer containing 100nM enaliprilat, 140 μ g/mL bacitracin and 0.1% BSA. 3H-des-arg10, leu9 kallidin is the radioligand used for the

human and rabbit B1 receptors, 3H-des-arg10 kallidin is used for the rat and dog B1 receptors, and 3H-bradykinin is used to label the human B2 receptor.

30 For all assays, compounds are diluted from DMSO stock solutions with 4 μ L added to assay tubes for a final DMSO concentration of 2%. This is followed by the addition of 100 μ L radioligand and 100 μ L of the membrane suspension. Nonspecific binding for the B1 receptor binding assays is determined using 1 μ M des-arg10 kallidin and nonspecific binding for the B2 receptor is determined with 1 μ M bradykinin. Tubes are incubated at room temperature (22°C) for 60 minutes followed by filtration using a Tomtec 96-well harvesting system. Radioactivity retained by the filter is counted using a Wallac Beta-plate scintillation counter.

35 The compounds of this invention have affinity for the B1 receptor in the above assay as demonstrated by results of less than 5 μ M. It is advantageous that the assay results be less than

1 μ M, even more advantageous for the results be less than 0.5 μ M. It is further advantageous that compounds of this invention have affinity for the bradykinin B1 receptor over the bradykinin B2 receptor; more advantageously, the affinity for the B1 receptor is at least 10 fold, and preferably over 100 fold, over that for the B2 receptor.

5

(b) Assay for Bradykinin B1 Antagonists

B1 agonist-induced calcium mobilization was monitored using a Fluorescence Imaging Plate Reader (FLIPR). CHO cells expressing the B1 receptor were plated in 96 or 384 well plates and allowed to incubate in Iscove's modified DMEM overnight. Wells were washed 10 two times with a physiological buffered salt solution and then incubated with 4uM Fluo-3 for one hour at 37°C. The plates were then washed two times with buffered salt solution and 100uL of buffer was added to each well. Plates were placed in the FLIPR unit and allowed to equilibrate for two minutes. The test compound was then added in 50ul volumes followed five minutes later by 50ul of agonist (des-arg¹⁰ kallidin). Relative fluorescence peak heights in the absence and 15 presence of antagonist were used to calculate the degree of inhibition of the B1 receptor agonist response by the test compound. Eight to ten concentrations of test compound were typically evaluated to construct an inhibition curve and determine IC₅₀ values using a four-parameter nonlinear regression curve fitting routine.

20 (c) Assay for Bradykinin Inverse Agonists

Inverse agonist activity at the human B1 receptor was evaluated using transiently transfected HEK293 cells. One day following transfection cell flasks were labeled overnight with 6uCi/ml [³H]myo-inositol. On the day of assay, the media was removed and the attached cells 25 were gently rinsed with 2x20ml of phosphate-buffered saline. Assay buffer (HEPES buffered physiological salts, pH 7.4) was added and the cells were detached by tapping of the flask. The cells were centrifuged at 800xg for five minutes and resuspended at 1x10⁶ cells/ml in assay buffer supplemented with 10mM lithium chloride. After 10 minutes at room temperature, one-half ml aliquots were distributed to tubes containing test compound or vehicle. After an additional 10 minutes the tubes were transferred to a 37°C water bath for 30 minutes. The 30 incubation was terminated by the addition of a 12% perchloric acid solution and the tubes were placed on ice for 30 minutes. The acid was then neutralized with KOH and the tubes centrifuged to pellet precipitated material. [³H]Inositol monophosphate formed was recovered by standard ion exchange chromatographic techniques and quantitated by liquid scintillation counting.

Inverse agonist activity was determined by the degree to which a test compound reduced basal (cells incubated with vehicle) levels of [³H]inositol monophosphate accumulation.


Abbreviations Used

5 The following abbreviations have the meanings indicated, unless stated otherwise in the specification: Ac=acetyl; Boc=t-butoxycarbonyl; Cat.=catalyst; DCM=dichloromethane; DMF=dimethylformamide; EDCI=1-(3-dimethylaminopropyl)-3-ethylcarbodiimide; Et=ethyl; HOBT=1-hydroxybenzotriazole; LAH=lithium aluminum hydride; LDA=lithium diisopropylamide; LiHMDS=lithium hexamethyldisilazide; Me=methyl; NBS=N-bromosuccinimide; 10 Ph=phenyl; Rt=room temperature; Tf=triflyl (trifluoromethanesulfonyl); THF=tetrahydrofuran.

Methods of Synthesis


Compounds of formula I may be prepared by the general procedure depicted in Scheme 1. The α -hydroxycarboxylic acid (1) is coupled with the arylmethylamine (2) using standard reagents and reaction conditions for amide bond formation, such as EDCI/HOBt.

SCHEME 1



20 The carboxylic acids (1) are commercially available or may be prepared from commercially available reagents using conventional chemical reactions well known in the art. The amines (2) may be prepared as outlined in Schemes 2 to 6. In Scheme 2, the biaryl derivative (5) is assembled using a Suzuki reaction between an aromatic boronic acid derivative (3), or an appropriate boronic ester derivative, and an aromatic halide (4) in the presence of a triarylphosphine, like triphenylphosphine, and a metal catalyst, like palladium acetate. The resultant cyano biphenyl intermediate (5), is then catalytically reduced to the biaryl amine derivative (2a) using hydrogen and a metal, like Raney Ni, in an appropriate solvent.


SCHEME 2



5 Alternatively, as illustrated in Scheme 3, the amine derivative (6), after primary amine protection with an appropriate protecting group, like Boc, is elaborated to the pinacol boron ester (8) using a palladium catalyst in an appropriate solvent, like dimethyl sulfoxide. This boron ester (8) is coupled to an aryl halide derivative (4) employing Suzuki reaction conditions to yield (2a) following deprotection.

10

SCHEME 3




15 A third method for the preparation of biaryl methanamine derivatives is depicted in Scheme 4. The biaryl moiety (11) is first assembled using a palladium catalyzed coupling of (9) with an aryl zinc compound (10) as shown. The methyl group of biaryl (11) is then elaborated according to the three step sequence of halogenation, nucleophilic displacement of the halogen

with azide, and reduction to provide the corresponding amine intermediate (2a). Alternatively, in a fourth method, the biarylmethanamine (2a) can also be prepared starting from the arylcarbonitrile (13) and aryl zinc compound (10) as previously discussed. The resulting biarylcarbonitrile (5) is then reduced using hydrogen to provide (2a).


5

SCHEME 4




10 A fifth method for the preparation of biarylmethanamine derivatives is depicted in Scheme 5. Reduction of the nitro group and nitrile hydrolysis of known pyridine (14) (*J. Chem. Soc.*, 1952, 2042-2046.) is followed by conversion of the resultant amine to the fluoride to afford (15). The amide is converted in a 3 step sequence to aldehyde (16). Imine formation with t-butyl sulfinamide is followed by addition of methyl Grignard to produce (17), which may be 15 further elaborated to provide the biarylmethanamine as shown above.

SCHEME 5.




5 The reaction steps in Scheme 6 illustrates the preparation of a compound of Formula (I) wherein R¹ is the benzisothiazoline moiety. While Scheme 6 depicts the preparation of a specific compound, the procedure may be used to prepare other similar compounds of Formula (I).

10 SCHEME 6



SCHEME 6 (cont'd)

5 Reference Examples

The following examples are provided to illustrate the preparation of the biaryl methyl amine starting materials. Other biaryl methyl amines may be similarly prepared.

I. Methyl 2-[6-(aminomethyl)-5-fluoropyridin-3-yl]-6-fluorobenzoate.

A solution of LDA (40.9 mmol, prepared from 11.4 mL of diisopropylamine and 16.4 mL of 2.5 M n-butyl lithium in hexanes) in 200 mL THF at -78°C was treated with 2-cyano-3-fluoropyridine (5.0 g, 40.9 mmol) in 50 mL of THF drop-wise. After 10 minutes a solution of iodine (10.4 g, 40.9 mmol) in 10 mL of THF was added. After 30 minutes the reaction was quenched with 40 mL of water followed by workup with aqueous sodium thiosulfate. The mixture was diluted with ether, washed with brine, dried over Na₂SO₄, filtered and concentrated under vacuum. The residue was subjected to silica gel chromatography eluted with 0-20% ethyl acetate in hexanes to provide 3-fluoro-4-iodopyridine-2-carbonitrile that gave proton NMR spectra consistent with theory.

A solution of LDA (16.9 mmol) in 200 mL THF at -78 °C was treated with the above carbonitrile (4.2 g, 16.9 mmol) in 50 mL of THF drop-wise. After 2 hours the reaction was quenched with water and warmed to room temperature. The mixture was diluted with ether, washed with brine, dried over Na₂SO₄, filtered and concentrated under vacuum. The residue was subjected to silica gel chromatography eluted with 0-20% ethyl acetate in hexanes to provide 3-fluoro-5-iodopyridine-2-carbonitrile that gave proton NMR spectra consistent with theory.

A solution of the above carbonitrile (1.08 g, 3.87 mmol) in 10 mL of THF and palladium tetrakis triphenylphosphine (0.18 g, 0.16 mmol) was added to a solution of [3-fluoro-2-(methoxycarbonyl)phenyl](iodo)zinc (prepared from methyl 2-fluoro-6-iodobenzoate and Reike Zinc) in 20 mL of THF via cannula. The mixture was heated to reflux for one hour,

cooled, and partitioned between ethyl acetate and water. The organic extract was washed with brine, dried over MgSO₄, filtered and concentrated under vacuum. The residue was subjected to silica gel chromatography eluted with 0-20% ethyl acetate in hexanes to provide methyl 2-(6-cyano-5-fluoropyridin-3-yl)-6-fluorobenzoate that gave proton NMR spectra consistent with theory.

To a stirred solution of the above ester (0.75 g, 2.7 mmol) in NH₃/MeOH (5 mL, 2.0 M) was added Raney 2800 nickel (slurry in water). The mixture was stirred under a H₂ atmosphere (balloon) at room temperature for 6 hours. The mixture was then filtered through glass filter paper, washing with additional MeOH. The resultant solution was concentrated under vacuum and azeotroped three times with toluene to provide crude title compound (0.65 g, 2.34 mmol).

II. (1R)-1-[5-[3,5-dichloro-2-(methoxycarbonyl)phenyl]-3-fluoropyridin-2-yl]ethanaminium chloride

A solution of 2,4-dichloro-6-hydroxybenzaldehyde (5.00g, 26.18 mmol) in 125 mL methanol was cooled to 0 °C. Perchloric acid (70%, 1.47 mL, 16.23 mmol) was added, and the solution was stirred for 10 minutes. To a separate flask, vanadium (V) oxide (0.190 g, 1.05 mmol) was added to a hydrogen peroxide solution (30% in H₂O, 11.90 mL, 104.7 mmol) at 0 °C. This solution was stirred until the catalyst was dissolved, resulting in a clear orange solution, which was added dropwise to the methanol solution. The reaction was allowed to slowly warm to room temperature and stir overnight. The solution was concentrated under vacuum, and the residue dissolved in ethyl acetate. The organic extract was washed with aqueous sodium bicarbonate and brine, dried over Na₂SO₄, filtered and concentrated. The residue was filtered through a silica gel plug with 10% ethyl acetate in hexanes to provide methyl 2,4-dichloro-6-hydroxybenzoate that gave proton NMR spectra consistent with theory.

A solution of the above ester (4.64g, 20.99 mmol) and pyridine (1.87 mL, 23.09 mmol) in 100 mL CH₂Cl₂ was cooled to 0 °C. Trifluoromethanesulfonic acid (4.94 mL, 29.39 mmol) was added, and the solution was stirred for 2h. The reaction mixture was washed with aqueous sodium bicarbonate, aqueous copper sulfate and brine, dried over Na₂SO₄, filtered and concentrated to provide methyl 2,4-dichloro-6-[(trifluoromethyl)sulfonyl]oxybenzoate that gave proton NMR spectra consistent with theory.

To a solution of 5-bromo-3-nitropyridine-2-carbonitrile (4.71 g, 20.7 mmol) in MeOH (319 mL) under N₂ was added tin(II) chloride dihydrate (27.97 g, 123.9 mmol). The reaction was heated to 40 °C for 40 minutes, concentrated in vacuo, and azeotroped with toluene. The residue was dissolved in ethyl acetate, and 10% aqueous sodium bicarbonate was added till

the solution was basic. The aqueous layer was extracted 3x with CHCl_3 and the combined organics were dried over Na_2SO_4 , filtered and concentrated under vacuum to provide 3-amino-5-bromopyridine-2-carboxamide that gave a mass ion (ES+) of 218.2 for $\text{M}+\text{H}^{+}(\text{Br})$.

To a solution of the above carboxamide (40.0 g, 185.2 mmol) in CH_2Cl_2 was added 5 nitrosonium tetrafluoroborate (22.71g, 191.4 mmol). The reaction was stirred at room temperature for 4.5 hours, then concentrated in vacuo and azeotroped with toluene. The residue was suspended in toluene (1100 mL) and heated to 100 °C for 2 hours. The reaction was concentrated in vacuo, and the residue suspended in CH_2Cl_2 . The solid was collected to provide 10 5-bromo-3-fluoropyridine-2-carboxamide that gave proton NMR spectra consistent with theory and a mass ion (ES+) of 219.1 for $\text{M}+\text{H}^{+}(\text{Br})$.

A solution of the above crude carboxamide (40.50 g, 184.9 mmol) in HCl (12N, 539.4 mL, 6.472 mol) was heated to 120 °C for 1 hour. The reaction was cooled to room temperature, and NaOH (20%) was added slowly to pH ~6. The solution was concentrated in vacuo, and azeotroped 3x with toluene. The residue was extracted thoroughly with 40% 15 MeOH/ CHCl_3 and filtered. This was repeated three times. The combined filtrates were concentrated and azeotroped 3x with toluene to provide 5-bromo-3-fluoropyridine-2-carboxylic acid that gave a mass ion (ES+) of 218.1 for $\text{M}+\text{H}^{+}(\text{Br})$.

A solution of the above crude arboxylic acid (40.65 g, 184.8 mmol), O,N-dimethyl-hydroxylamine hydrochloride (21.63 g, 221.7 mmol), 1-ethyl-(3-dimethylaminopropyl)-carbo-20 diimide hydrochloride (70.85 g, 369.6 mmol), 1-hydroxy-7-azabenzotriazole (2.497 g, 18.48 mmol), and triethylamine (16.48 mL, 118.3 mmol) in 200 mL DMF was stirred at RT overnight. The solution was partially concentrated in vacuo and partitioned between ethyl acetate and 10% aqueous sodium bicarbonate. The aqueous layer was extracted 4x with ethyl acetate, and the combined organics were washed with water and brine, dried over Na_2SO_4 , filtered and 25 concentrated under vacuum to provide 5-bromo-3-fluoro-N-methoxy-N-methylpyridine-2-carboxamide that gave proton NMR spectra consistent with theory and a mass ion (ES+) of 263.01 for $\text{M}+\text{H}^{+}(\text{Br})$.

To a solution of the above crude carboxamide (27.94 g, 106.2 mmol) in THF (350 mL) at -78 °C was added LAH (1M in THF, 45.67 mL, 45.67 mmol) dropwise. The reaction was 30 stirred at -78 °C for 2 hours, then H_2O (100 mL) and brine (100 mL) were added. The mixture was warmed to RT and partially concentrated in vacuo, diluted with ethyl acetate and filtered through celite. The aqueous layer was extracted 4x with ethyl acetate. The combined organics were washed with brine, dried over Na_2SO_4 , filtered and concentrated under vacuum. The residue was filtered through a silica gel plug with 10% ethyl acetate in hexanes to provide 35 5-bromo-3-fluoropyridine-2-carbaldehyde that gave proton NMR spectra consistent with theory.

To a solution of (R)-(+)-2-methyl-2-propanesulfinamide (9.898 g, 81.67 mmol) in CH₂Cl₂ (160 mL) was added 5-bromo-3-fluoropyridine-2-carbaldehyde (16.66 g, 81.67 mmol), pyridinium *p*-toluenesulfonate (1.026 g, 4.08 mmol), and magnesium sulfate (49.15 g, 408.3 mmol). The reaction was stirred at room temperature overnight, then filtered through celite and concentrated in vacuo. The residue was subjected to silica gel chromatography eluted with 0 to 5 10% ethyl acetate in hexanes to provide N-[(1E)-(5-bromo-3-fluoropyridin-2-yl)methylidene]-2-methylpropane-2-sulfinamide that gave proton NMR spectra consistent with theory and a mass ion (ES+) of 307.0 for M+H⁺ (⁸¹Br).

A solution of the above sulfinamide (18.63 g, 60.65 mmol) in CH₂Cl₂ (375 mL) was 10 cooled to -50 °C under N₂. Methylmagnesium chloride (3M in THF, 30.32 mL, 90.97 mmol) was added dropwise, the reaction was stirred for 1h. Additional methylmagnesium chloride (5.0 mL, 15.0 mmol) was added after 30 minutes to drive the reaction to completion. Water (200 mL) and brine (200 mL) were added, and the reaction allowed to warm to room temperature. 15 The aqueous layer was extracted 4x with CH₂Cl₂, and the combined organics were dried over Na₂SO₄, filtered and concentrated under vacuum. The residue was subjected to silica gel chromatography eluted with 10-40% ethyl acetate in hexanes to provide N-[(1R)-1-(5-bromo-3-fluoropyridin-2-yl)ethyl]-2-methylpropane-2-sulfinamide that gave proton NMR spectra consistent with theory and a mass ion (ES+) of 325.0 for M+H⁺ (⁸¹Br).

A mixture of the above sulfinamide (0.500 g, 1.55 mmol), bis(pinacolato)diboron 20 (0.412 g, 1.62 mmol), potassium acetate (0.456 g, 4.64 mmol), and [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride (0.030 g, 0.041 mmol) in 5 mL DMF was heated to 90 °C under N₂ for 4 hours. Additional bis(pinacolato)diboron (0.295 g, 1.16 mmol) and 3-chloroperoxybenzoic acid (861 mg, 4.99 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]-palladium(II) dichloride (0.030 g, 0.041 mmol) were added to drive the reaction to completion. 25 The reaction mixture was cooled to room temperature, and methyl 2,4-dichloro-6-[(trifluoromethyl)sulfonyl]oxy]benzoate (0.546 g, 1.55 mmol), sodium carbonate (2M, 2.32 mL, 4.64 mmol), and [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride (0.003 g, 0.041 mmol) were added. The reaction mixture was heated to 90 °C 1.5 hours, then cooled to room temperature and partitioned between ethyl acetate and water. The organic extract was washed 30 with water and brine, dried over Na₂SO₄, filtered and concentrated under vacuum. The residue was subjected to silica gel chromatography eluted with 0-30% ethyl acetate in hexanes to provide methyl 2-(6-[(1R)-1-[(tert-butylsulfinyl)amino]ethyl]-5-fluoropyridin-3-yl)-4,6-dichlorobenzoate that gave proton NMR spectra consistent with theory.

To a solution of the above product in methanol (1.2 mL) was added HCl/dioxane solution (4M, 1.2 mL, 4.6 mmol). The solution was stirred at room temperature 30 minutes, then concentrated in vacuo to provide the title compound (ES+) of 343.01 for M+H⁺.

5 III. Methyl 4'-(1R)-1-aminoethyl]-3-fluoro-1,1'-biphenyl-2-carboxylate HCl.

Commercially available (1R)-1-(4-bromophenyl)ethanamine was Boc protected, using standard procedures known to those skilled in the art, to produce *tert*-butyl (1R)-1-(4-bromophenyl)ethylcarbamate.

To a solution of the above carbamate (7.6 g, 25.3 mmol) in DMSO (20 mL) was added bis(pinacolato)diboron (7.07 g, 27.9 mmol), dichloro[1,1'-bis(diphenylphosphino)-ferrocene]palladium (II) dichloromethane adduct (2.06 g, 2.53 mmol), and potassium acetate (7.45 g, 76.0 mmol) at room temperature under N₂. The resulting mixture was heated at 80 °C for 1 hour. The reaction was quenched by addition of EtOAc and filtered through celite. The organic extract was washed with water three times, saturated NaCl, dried over MgSO₄, filtered and concentrated under vacuum. The residue was purified on silica gel eluted with 0-20% ethyl acetate in hexane to provide *tert*-butyl (1R)-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-phenyl]ethylcarbamate as a clear light yellow oil with a mass ion (ES+) of 333.


To a stirred solution of the above carbamate (1.0 g, 2.9 mmol) and methyl 2-fluoro-6-iodobenzoate (1.2 g, 4.32 mmol) in 25 mL of a 5:1 THF:water mixture was added potassium carbonate (1.2 g, 8.64 mmol), tri-*o*-tolylphosphine (350 mg, 1.15 mmol) and lastly palladium acetate (65 mg, 0.29 mmol). The reaction vessel was then sealed and placed into a 90 °C oil bath for overnight stirring and heating. After about 18 hours the reaction mixture was cooled to ambient temperature and then diluted with EtOAc. The organics were washed with brine (x4), dried over sodium sulfate, filtered, and concentrated under reduced pressure to give an oil. This oil was subject to silica gel chromatography eluting with 10-60% EtOAc in hexanes to provide methyl 4'-(1R)-1-[(*tert*-butoxycarbonyl)amino]ethyl]-3-fluoro-1,1'-biphenyl-2-carboxylate (205 mg), found to be pure by LC/MS and proton NMR.

The above carboxylate (205 mg, 0.60 mmol) dissolved in MeOH (15 mL) was cooled to 0 °C. This homogenous solution was saturated with anhydrous HCl and allowed to sit for 20 minutes. Dry nitrogen was then bubbled through the solution for about 30 minutes. Solvent was then removed under reduced pressure to yield an oily residue. The oil was then dissolved in DCM and the solvent removed. This process was repeated until a solid amine hydrochloride was obtained.

The following examples are provided to illustrate the invention are not to be construed as limiting the scope of the claims in any manner.

EXAMPLE 1


5 Methyl 4'-([(1-hydroxycyclopropyl)carbonylamino]methyl)biphenyl-2-carboxylate



Methyl 4'-(aminomethyl)biphenyl-2-carboxylate (0.325 g, 1.35 mmol), 1-hydroxy-10 cyclopropanecarboxylic acid (0.151 g, 1.48 mmol) and 1-hydroxybenzotriazole hydrate (0.248 g, 1.62 mmol) were suspended in a mixture of THF/DCM (13 mL of THF/6.5 mL of DCM), followed by the addition of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.336 g, 1.75 mmol). Rapidly the solution turned homogenous, but returned to a heterogeneous mixture after 5 minutes. After 3 hours the solvent mixture was exchanged for pure DCM, prior 15 to purification by silica gel chromatography eluted with 1-5% methanol in DCM to provide the title compound.


20 LRMS (ES, M+H⁺): 326. ¹H NMR (400 MHz, CDCl₃): δ 7.84 (dd, *J* = 8.0, 1.2 Hz, 1H), 7.53 (td, *J* = 7.6, 1.6 Hz, 1H), 7.41 (td, *J* = 7.6, 1.2 Hz, 1H), 7.34 (m, 3H), 7.29 (bd, *J* = 8.4 Hz, 2H), 7.19 (bs, 1H), 4.55 (d, *J* = 6.0 Hz, 2H), 3.69 (s, 3H), 2.55 (bs, 1H), 1.43 (m, 2H), 1.07 (m, 2H).

25 The following compounds were prepared by following the general procedure provided in Example 1. The α-hydroxycarboxylic acid starting materials are either commercially available or may be prepared from commercially available reagents using conventional reactions well known in the art. The biaryl methylamine starting materials may be prepared by the procedures provided in the Reference Examples section and in the general reaction schemes, using reagents that are either commercially available or that may be prepared from commercially available reagents using conventional reactions well known in the art.




Ex.	R2a	R2b	*	LRMS (M+H ⁺)
2	CH ₃	CH ₃	-	364
3	H	H	-	336
4	CH ₂ CH ₃	CH ₂ CH ₃	-	392
5	3-(OCH ₃)-Ph	H	±	442
6	CHCH ₃	CH ₃	±	378
7	CH(CH ₃) ₂	H	±	378
8	CH ₃	H	S	350
9	Ph	cyclopentyl	±	480
10	4-Br-Ph	H	±	490
11	4-(CF ₃)-Ph	H	±	480
12	Ph	H	S	412
13	4-(OCH ₃)-Ph	H	±	442
14	CH ₂ Ph	H	±	426
15	cyclohexyl	H	R	418
16	3-(OH)-4-(OCH ₃)-Ph	H	±	458
17	3,4-diOH-Ph	H	±	444
18	CF ₃	CF ₃	-	472
19	CH ₂ CH(CH ₃) ₂	H	±	392
20	Ph	CH ₃	±	426
21	(1H-indol-3-yl)methyl	H	±	465
22	CH ₂ (CH ₂) ₄ CH ₃	H	±	420
23	3,5-diF-Ph	H	±	448
24	CF ₃	H	±	404
25	CF ₃	CH ₃	S	418
26	CF ₃	CH ₃	R	418
27	CH ₃	H	R	350

Ex.	R ^{2a}	R ^{2b}	*	LRMS (M+H ⁺)
28	(CH ₂) ₃ CH ₃	H	±	392
29	cyclohexyl	H	S	418
30	CH ₂ CH(CH ₃) ₂	H	S	392
31	CH(CH ₃) ₂	H	R	378
32	CH(CH ₃) ₂	H	S	378
33	CH(CH ₃)CH ₂ CH ₃	H	S	392
34	C(CH ₃) ₃	H	S	392
35	CF ₃	H	S	404
36	CH ₂ CH ₂ SCH ₃	H	±	410
37	CH ₂ CH(CH ₃) ₂	H	R	392
38	(pyridin-3-yl)methyl	H	±	427



Ex.	m	R ^{3a}	Y	*	R ⁶	R ⁷	R ⁸	R ⁹	LRMS (M+H ⁺)
39	1	H	CH	-	CO ₂ CH ₃	F	F	H	362
40	2	H	CH	-	CO ₂ CH ₃	F	F	H	376
41	1	CH ₃	N	R	CO ₂ CH ₃	F	Cl	Cl	427
42	5	H	CH	-	CO ₂ CH ₃	F	F	H	418
43	1	CH ₃	N	R	OCH ₂ CH ₃	F	Cl	Cl	413
44	1	CH ₃	CH	R	CO ₂ CH ₃	F	Cl	H	392
45	1	CH ₃	CH	R	CO ₂ CH ₃	H	F	H	358
46	1	CH ₃	CH	S	CO ₂ CH ₃	F	F	H	376
47	1	CH ₃	N	R	OCH ₂ CHF ₂	F	Cl	Cl	449
48	1	CH ₃	CH	R	CO ₂ CH ₃	Cl	Cl	H	408
49	1	CH ₃	CH	R	OCH ₂ CHF ₂	F	Cl	Cl	448


Ex.	m	R ^{3a}	Y	*	R ⁶	R ⁷	R ⁸	R ⁹	LRMS (M+H ⁺)
50	1	CH ₃	CH	R	2-CH ₃ -2H-tetrazol-5-yl	F	F	H	400
51	1	CH ₃	CH	R	CO ₂ CH ₃	F	Cl	Cl	426
52	2	CH ₃	N	R	CO ₂ CH ₃	F	Cl	Cl	441
53	1	CH ₃	N	R	2-CH ₃ -2H-tetrazol-5-yl	F	F	H	401



Example	Y	*	R ⁶	R ⁷	R ⁸	R ⁹	LRMS (M+H ⁺)
54	CH	R	CO ₂ CH ₃	F	Cl	H	448
55	N	R	CO ₂ CH ₃	F	F	Cl	467
56	N	R	2-CH ₃ -2H-tetrazol-5-yl	F	F	H	457
57	N	R	CO ₂ CH ₂ CH ₃	F	F	Cl	481
58	N	R	CO ₂ CH ₃	F	Cl	Cl	483
59	N	R	OCH ₂ CHF ₂	F	Cl	Cl	505
60	N	R	OCH ₂ CH ₃	F	Cl	Cl	469
61	CH	R	2-CH ₃ -2H-tetrazol-5-yl	F	F	H	456
62	CH	±	Ph	F	H	H	432
63	CH	R	CO ₂ CH ₃	F	Cl	Cl	482

WHAT IS CLAIMED IS:


1. A compound of formula (I) and pharmaceutically acceptable salts thereof



wherein

Y is CH or N;

10 R1 is



R2a and R2b are independently selected from

(1) a group selected from Ra,

(2) $(CH_2)_nNR^bC(O)R^a$,

15 (3) $(CH_2)_nNR^bSO_2R^d$,

(4) $(CH_2)_nNR^bCO_2R^a$,

(5) $(CH_2)_k$ -heterocycle optionally substituted with 1 to 3 groups independently selected from halogen, nitro, cyano, OR^a, SR^a, C₁₋₄ alkyl and C₁₋₃ haloalkyl wherein said heterocycle is (a) a 5-membered heteroaromatic ring having a ring heteroatom selected from N, O and S, and optionally having up to 3 additional ring nitrogen atoms wherein said ring is

20 optionally benzo-fused; or (b) a 6-membered heteroaromatic ring containing from 1 to 3 ring nitrogen atoms and N-oxides thereof, wherein said ring is optionally benzo-fused,

(6) $(CH_2)_kCO_2R^a$, and

(7) $(CH_2)_kC(O)NR^bR^c$, or

25 R2a and R2b together with the carbon atom to which they are attached form a 3- to 7-membered carbocyclic ring optionally substituted with 1 to 4 groups independently selected from halogen, OR^a, C₁₋₄ alkyl and C₁₋₄ haloalkyl;

R^{3a} and R^{3b} are independently selected from hydrogen and C₁-4 alkyl optionally substituted with 1 to 5 halogen atoms;

R^{4a} and R^{4b} are independently selected from hydrogen and halogen;

R⁶ is selected from

5 (1) C₁-8 alkyl optionally substituted with 1-5 groups independently selected from halogen, nitro, cyano, COR^a, CO₂R^a, C(O)NR^bR^c, OR^a, OC(O)R^a, SR^a, SO₂R^d, S(O)R^d, NR^bRC, NR^bC(O)R^a, NR^bSO₂R^d, and NR^bCO₂R^a,

10 (2) C₃-8 cycloalkyl,

(3) C₂-8 alkenyl optionally substituted with CO₂R^a,

15 (4) halogen,

(5) cyano,

(6) nitro,

(7) NR^bRC,

(8) NR^bC(O)R^a,

(9) NR^bCO₂R^a,

(10) NR^bC(O)NR^bRC,

(11) NR^bC(O)NR^bCO₂R^a,

(12) NR^bSO₂R^d,

(13) CO₂R^a,

20 (14) COR^a,

(15) C(O)NR^bRC,

(16) C(O)NHOR^a,

(17) C(=NOR^a)R^a,

(18) C(=NOR^a)NR^bRC,

25 (19) OR^a,

(20) OC(O)R^a,

(21) S(O)_vR^d,

(22) SO₂NR^bRC,

(23) optionally substituted heterocycle where the heterocycle is a 5-membered

30 heteroaromatic ring having a ring heteroatom selected from N, O and S, and optionally having up to 3 additional ring nitrogen atoms, 4,5-dihydro-oxazolyl or 4,5-dihydro-1,2,4-oxadiazolyl, and wherein said substituent is 1 to 3 groups independently selected from C₁-4 alkyl optionally substituted with 1 to 5 halogen atoms, OR^a or OC(O)R^a,

(24) phenyl or pyridyl, each optionally substituted with 1 to 3 groups independently selected from halogen, nitro, cyano, OR^a, SR^a, C₁₋₄ alkyl and C₁₋₃ haloalkyl, and

(25) OSO₂R^d;

R⁷ is selected from hydrogen and halogen;

5 R⁸ and R⁹ are independently selected from hydrogen and a group from R⁶; with the proviso that not more than one of R⁶, R⁸, and R⁹ is a heterocycle;

R^a is selected from

(1) hydrogen,

(2) C₁₋₇ alkyl optionally substituted with 1 to 5 halogen atoms, OH, SH,

10 O-C₁₋₄alkyl, or S-C₁₋₄alkyl,

(3) (CH₂)_k-phenyl optionally substituted with 1 to 3 groups independently selected from halogen, cyano, nitro, OH, C₁₋₄ alkyloxy, C₃₋₆ cycloalkyl and C₁₋₄ alkyl optionally substituted with 1 to 5 halogen atoms,

(4) C₃₋₆ cycloalkyl,

15 (5) (CH₂)_k-pyridyl, and

(6) (CH₂)_k-indolyl;

R^b and R^c are independently selected from

(1) hydrogen,

(2) C₁₋₄ alkyl optionally substituted with 1 to 5 groups independently selected from halogen, amino, CO₂R^a, OR^a, mono-C₁₋₄alkylamino, and di-C₁₋₄alkylamino,

(3) (CH₂)_k-phenyl optionally substituted with 1 to 3 groups selected from halogen, cyano, nitro, OR^a, CO₂R^a, C₃₋₆ cycloalkyl and C₁₋₄ alkyl optionally substituted with 1 to 5 halogen atoms,

(4) C₃₋₆ cycloalkyl, or

25 R^b and R^c together with the nitrogen atom to which they are attached form a 4-, 5-, or 6-membered ring optionally containing an additional heteroatom selected from NRe, O, S, S(O) and S(O)₂;

R^d is selected from

(1) C₁₋₄ alkyl optionally substituted with 1 to 5 halogen atoms,

30 (2) C₁₋₄ alkyloxy,

(3) (CH₂)_k-phenyl optionally substituted with 1 to 3 groups selected from halogen, cyano, nitro, OR^a, CO₂R^a, C₃₋₆ cycloalkyl and C₁₋₄ alkyl optionally substituted with 1 to 5 halogen atoms,

(4) pyridyl, and

35 (5) pyridyl N-oxide;


R^e is selected from hydrogen, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C(O)H and C(O)C₁₋₄alkyl;
 n is 1, 2, or 3;
 k is 0, 1, 2, 3, or 4; and
 v is 0, 1, or 2.

5

2. A compound of Claim 1 wherein R^{2a}, R^{2b} and the carbon atom to which they are attached form a 3- to 7-membered carbocyclic ring optionally substituted with 1 to 4 groups independently selected from halogen, OR^a, C₁₋₄ alkyl and C₁₋₄ haloalkyl.

10

3. A compound of Claim 1 wherein R¹ is




wherein R⁶, R⁸ and R⁹ are as defined in Claim 1.

15 4. A compound of Claim 3 wherein R⁶ is selected from (1) -CO₂-C₁₋₄alkyl, (2) C₁₋₄alkoxy, and (3) a 5-membered heteroaromatic ring having a ring heteroatom selected from N, O and S, and optionally having up to 3 additional ring nitrogen atoms, said ring being optionally substituted with a C₁₋₄alkyl group.

20 5. A compound of Claim 4 wherein R⁸ is hydrogen or 3-halo, and R⁹ is hydrogen or 5-halo.

6. A compound of Claim 1 wherein R¹ is




, wherein R^{4a}, R^{4b} and R^a are as defined in Claim 1.

25

7. A compound of Claim 1 wherein R^{4a} and R^{4b} are each fluoro.


8. A compound of Claim 1 having the formula (Ia):



5 wherein m is 1 to 5; Y is N or CH; one of R^{3a} and R^{3b} is hydrogen and the other is hydrogen or methyl; R⁷ is hydrogen or fluorine; R⁶ is selected from (1) -CO₂-C₁₋₄alkyl, (2) C₁₋₄alkoxy, and (3) a 5-membered heteroaromatic ring having a ring heteroatom selected from N, O and S, and optionally having up to 3 additional ring nitrogen atoms, said ring being optionally substituted with a C₁₋₄alkyl group; and R⁸ and R⁹ are independently hydrogen or halogen.

10

9. A compound of Claim 1 having the formula Ib:




15 where R^{3a}, R^{3b}, R⁶, R⁷, R⁸ and R⁹ are as defined in Claim 1, and R^{2a'} and R^{2b'} are independently selected from (1) hydrogen, (2) C₁₋₇ alkyl optionally substituted with 1 to 5 halogen atoms, SH, OH, S-C₁₋₄alkyl or OC₁₋₄alkyl, (3) (CH₂)_k-phenyl optionally substituted with 1 to 3 groups independently selected from halogen, cyano, nitro, OH, C₁₋₄ alkyloxy, C₃₋₆ cycloalkyl and C₁₋₄ alkyl optionally substituted with 1 to 5 halogen atoms, (4) C₃₋₆ cycloalkyl, 20 (5) (CH₂)_k-pyridyl, and (6) (CH₂)_k-indolyl.

10. A compound of Claim 9 wherein R^{2a'} and R^{2b'} are independently C₁₋₇alkyl optionally substituted with 1 to 5 halogen atoms.

25 11. A compound of Claim 10 wherein one of R^{3a} and R^{3b} is hydrogen and the other is hydrogen or methyl; R⁷ is hydrogen or fluorine; R⁶ is selected from (1) -CO₂-C₁₋₄alkyl, (2) C₁₋₄alkoxy optionally substituted with 1 to 5 halogen atoms, and (3) a 5-membered

heteroaromatic ring having a ring heteroatom selected from N, O and S, and optionally having up to 3 additional ring nitrogen atoms, said ring being optionally substituted with a C₁-4alkyl group; and R⁸ and R⁹ are independently hydrogen or halogen.

5 12. A compound of Claim 1 having the formula Ic:



10 wherein Y is N or CH; R⁷ is H or fluroine; R⁶ is selected from (1) -CO₂-C₁-4alkyl, (2) C₁-4alkoxy optionally substituted with 1 to 5 halogen atoms, and (3) a 5-membered heteroaromatic ring having a ring heteroatom selected from N, O and S, and optionally having up to 3 additional ring nitrogen atoms, said ring being optionally substituted with a C₁-4alkyl group; and R⁸ and R⁹ are independently hydrogen or halogen.

15 13. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 and a pharmaceutically acceptable carrier.

20 14. A method for the treatment or prevention of a condition mediated by bradykinin B1 receptor in a mammal which comprises administering to said mammal a therapeutically effective amount of a compound of Claim 1.

15. A method for the treatment or prevention of pain in a mammal which comprises administering to said mammal a therapeutically effective amount of a compound of Claim 1.

25 16. A method for the treatment or prevention of pain selected from acute pain, inflammatory pain and neuropathic pain in a mammal which comprises administering to said mammal a therapeutically effective amount of a compound of Claim 1.

ABSTRACT OF THE DISCLOSURE

α -Hydroxy amide derivatives are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.